1456P Long-term survivorship rates for first-line intermediate or poor (I/P) risk advanced renal cell carcinoma (aRCC) patients achieving objective response (OR) with nivolumab plus ipilimumab (N+I)

Abstract

Long-term (minimum 60-month) follow-up from the CheckMate 214 study showed high OR rate (42%) and durable response benefits with a yet to be reached median duration of response (DoR) for I/P risk aRCC patients treated with N+I. This led to sustained survival plateaus implying the possibility of long-term survivors (LTS), which can be estimated via mixture cure models (MCMs).